Author: Kidney- Hub

A practical review of atrasentan in IgA nephropathy: patient selection, ALIGN kidney-function data, safety, and whether the potential benefit justifies the cost.

A practical evidence review of contemporary IgA nephropathy therapy, showing how to match new treatments to risk, safety, monitoring, and local labels.

A clinically focused review of 10 landmark nephrology studies from 2006–2026 that changed CKD, dialysis, glomerular, AKI, ADPKD, and diabetic-kidney-disease practice.

GLP-1 receptor agonists and next-generation metabolic hormone therapies are reshaping obesity, diabetes and cardiovascular care, with an increasingly important role in CKD risk reduction.

Engineered WNT-secreting organizers improve nephron patterning in human kidney organoids, illustrating how spatial developmental signals may create more faithful models of the developing kidney.

A 2026 preclinical study used a microneedle biosensor to estimate drug clearance continuously in animal models. The technology is promising but remains experimental rather than a clinical kidney-function test.

Insulin has direct renal actions involving podocytes, tubular sodium handling and gluconeogenesis, so insulin resistance may contribute to CKD beyond its role as a precursor to diabetes.

Spatial transcriptomics suggests that sepsis-associated AKI consists of localized inflammatory, vascular and tubular niches rather than a uniform kidney-wide injury pattern.

Spatial omics adds molecular information to the anatomical context of kidney tissue and may enable more precise renal disease phenotyping alongside digital pathology and AI.

Potassium is both a nutrient and a distal-nephron signal linking dietary intake, sodium handling and blood pressure, with important implications for CKD counseling.

Long-term ALIGN data strengthen the evidence for atrasentan in IgA nephropathy, while the broader treatment landscape increasingly targets multiple pathways involved in progression.